Jun. 14 at 12:26 AM
$ANNX Annexon's drug appears "be at least as equivalent to existing therapies and possibly better," said Hugh Willison, professor emeritus of neurology at the University of Glasgow, while noting that details on the trial were scarce.
If approved, the company plans to supply the drug through a manufacturing partnership with Swiss pharmaceutical supplier Lonza (LONN.S), opens new tab.
